Amalgamated Bank lowered its position in shares of Teladoc Health, Inc. (NYSE:TDOC – Get Rating) by 3.9% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,278 shares of the health services provider’s stock after selling 628 shares during the period. Amalgamated Bank’s holdings in Teladoc Health were worth $1,102,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in the company. McCarthy Asset Management Inc. purchased a new stake in shares of Teladoc Health in the 1st quarter worth about $25,000. DB Wealth Management Group LLC purchased a new stake in shares of Teladoc Health in the 1st quarter worth about $25,000. City State Bank purchased a new stake in shares of Teladoc Health in the 4th quarter worth about $27,000. Oliver Lagore Vanvalin Investment Group purchased a new stake in shares of Teladoc Health in the 1st quarter worth about $27,000. Finally, GoalVest Advisory LLC purchased a new position in Teladoc Health during the 1st quarter valued at about $31,000. Hedge funds and other institutional investors own 92.46% of the company’s stock.
Insider Buying and Selling at Teladoc Health
In other Teladoc Health news, SVP Daniel Trencher sold 1,000 shares of Teladoc Health stock in a transaction that occurred on Monday, July 18th. The shares were sold at an average price of $41.12, for a total transaction of $41.120.00. Following the transaction, the senior vice president now owns 27,408 shares of the company’s stock, valued at $1,127,016.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Teladoc Health news, insider Arnnon Geshuri sold 4,098 shares of Teladoc Health stock in a transaction that occurred on Friday, August 26th. The shares were sold at an average price of $34.27, for a total transaction of $140,438.46. Following the transaction, the insider now owns 76,182 shares of the company’s stock, valued at $2,610,757.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Daniel Trencher sold 1,000 shares of the business’s stock in a transaction on Monday, July 18th. The stock was sold at an average price of $41.12, for a total transaction of $41.120.00. Following the completion of the transaction, the senior vice president now directly owns 27,408 shares in the company, valued at approximately $1,127,016.96. The disclosure for this sale can be found here. Insiders have sold 7,318 shares of company stock valued at $255,321 over the last 90 days. 1.55% of the stock is currently owned by corporate insiders.
Teladoc Health Stock Performance
TDOC opened at $28.20 on Thursday. The company has a current ratio of 3.38, a quick ratio of 3.22 and a debt-to-equity ratio of 0.25. The company has a market cap of $4.55 billion, a price-to-earnings ratio of -0.46 and a beta of 0.86. The company’s 50 day moving average is $34.10 and its 200 day moving average is $41.84. Teladoc Health, Inc. has a 12-month low of $26.12 and a 12-month high of $156.82.
Teladoc Health (NYSE:TDOC – Get Rating) last posted its quarterly earnings data on Wednesday, July 27th. The health services provider reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.27. The company had revenue of $592.38 million for the quarter, compared to the consensus estimate of $586.86 million. Teladoc Health had a negative net margin of 441.94% and a negative return on equity of 2.04%. On average, equities research analysts predict that Teladoc Health, Inc. will post -1.54 EPS for the current year.
Analysts Set New Price Targets
A number of brokerages recently issued reports on TDOC. Guggenheim cut shares of Teladoc Health from a “neutral” rating to a “sell” rating and set a $25.00 price target for the company. in a research report on Wednesday, August 17th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Teladoc Health from $34.00 to $31.00 and set a “hold” rating for the company in a research report on Tuesday. Bank of America lifted their price target on shares of Teladoc Health from $36.00 to $42.00 and gave the company a “neutral” rating in a research report on Wednesday, July 6th. The Goldman Sachs Group cut shares of Teladoc Health from a “buy” rating to a “neutral” rating and lowered their price target for the company from $55.00 to $36.00 in a research report on Thursday, July 28th. Finally, Canaccord Genuity Group lowered their price target on shares of Teladoc Health from $50.00 to $45.00 in a research report on Thursday, July 28th. Two research analysts have rated the stock with a sell rating, twenty-four have issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Teladoc Health has an average rating of “Hold” and a consensus target price of $64.13.
Teladoc Health Profile
(Get Rating)
Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions.
See Also
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health, Inc. (NYSE:TDOC – Get Rating).
Receive News & Ratings for Teladoc Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teladoc Health and related companies with MarketBeat.com’s FREE daily email newsletter.